SCHEDULE: Ligand to Acquire XOMA Royalty for $39 Per Share Plus CVRs

Ligand Pharmaceuticals has entered into a definitive agreement to acquire XOMA Royalty Corporation in an all-cash transaction valued at $39.00 per share plus contingent value rights.

Summary

• Ligand Pharmaceuticals is acquiring 100% of XOMA Royalty Corporation.
• Common stockholders will receive $39.00 per share in cash at closing.
• Shareholders will also receive Contingent Value Rights (CVRs) representing 75% of net proceeds from the Janssen Litigation.
• Supporting stockholders, including BVF Partners and company directors, representing approximately 47% of voting power have agreed to vote in favor of the deal.
• The transaction involves a complex Holding Company Reorganization and a CVR Spin-off into a dedicated trust.
• XOMA is subject to a $40 million termination fee if the deal is cancelled under specific circumstances, such as accepting a superior proposal.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive event for XOMA shareholders, providing a substantial cash floor while maintaining exposure to legal upside with high closing certainty.

Positives

• Cash consideration of $39.00 per share provides immediate liquidity to shareholders.
• Retention of 75% of net proceeds from the Janssen Litigation via CVRs offers significant potential upside.
• The deal is not subject to any financing condition, increasing the certainty of closing.
• Strong initial support with 47% of the voting power already committed via Support Agreements.

Negatives

• A $40 million termination fee may discourage other potential bidders from making a superior offer.
• Customary 'no-shop' restrictions limit the company's ability to actively solicit alternative acquisition proposals.
• The transaction structure is complex, requiring a multi-step reorganization and conversion of preferred stock.

Risks

• The merger is subject to approval by a majority of XOMA stockholders.
• Regulatory approval under the Hart-Scott-Rodino (HSR) Act is required and could be delayed or denied.
• The Janssen Litigation may result in no recovery, rendering the CVRs worthless.
• Ligand has the right to negotiate modifications if material adverse consequences are identified during the reorganization process.

Future Outlook

The transaction is expected to proceed through a stockholder vote and regulatory review, with a target completion date on or before January 26, 2027. The ultimate value to shareholders will depend on the outcome of the Janssen Litigation.

Management Comments

• The purpose of the Merger is for Ligand to acquire control of, and the entire equity interest in, the Issuer.
• Ligand disclaims beneficial ownership of the shares covered by the Support Agreements except for the purposes of Section 13(d).

Industry Context

StockSavvy.ai notes that this acquisition follows a trend of consolidation in the pharmaceutical royalty space, where larger players like Ligand seek to scale their portfolios by acquiring specialized royalty aggregators like XOMA.

Comparison to Industry Standards

• The $39.00 cash offer represents a structured exit typical for biotech royalty companies with pending litigation assets.
• The use of a CVR to bridge valuation gaps regarding legal outcomes is a standard industry practice, similar to structures used in major pharma acquisitions like the Celgene/Bristol-Myers Squibb deal.
• The 47% lock-up via support agreements is higher than the typical 10-20% seen in many mid-cap mergers, suggesting high deal certainty.

Corporate Governance

Legal Proceedings

• The Janssen Litigation is the primary asset underlying the Contingent Value Rights (CVRs).

Related Party Transactions

• Support Agreements were entered into with XOMA's officers, directors, and funds affiliated with BVF Partners.

Stakeholder Impact

• Common shareholders receive cash and potential future payments.
• Preferred stockholders will have their shares redeemed for cash plus accrued dividends.
• Ligand gains full control of XOMA's royalty portfolio and business operations.

Next Steps

• Filing of a proxy statement with the SEC.
• Convening a special meeting of XOMA stockholders to approve the merger.
• Expiration or termination of the HSR Act waiting period.
• Completion of the Holding Company Reorganization and CVR Spin.
• Redemption of Series A and Series B Perpetual Preferred Stock.

Key Dates

Recommendation

The deal offers a clear cash premium with a high probability of closing due to the 47% voting lock-up, plus a 'free' call option on the Janssen Litigation via the CVRs. Arbitrageurs and long-term investors alike would find the risk-reward profile attractive at prices near or below the $39.00 cash floor.

Keywords

Acquisition, Merger, Pharmaceuticals, Royalty Assets, CVR, Janssen Litigation, Ligand Pharmaceuticals, XOMA Royalty, Schedule 13D